WHEREAS, Experience shows that increasing cervical cancer
awareness among women, especially underserved women,
significantly reduces the probability of mortality; and
WHEREAS, Cervical cancer disproportionately affects minority
women and women with lower incomes who are less likely to have
access to routine screenings; and
WHEREAS, Approximately half of all cervical cancer cases are
in women who have never been screened and 10% of cases are in
women who have not been screened within the last five years; and
WHEREAS, The majority of cervical cancer patients are
diagnosed before 50 years of age, the youngest median age for
all female reproductive cancers; and
WHEREAS, New screening technologies offer advanced
opportunities to eliminate cervical cancer through early
identification of women at increased risk; and
WHEREAS, These technologies include testing approved by the
United States Food and Drug Administration for human
papillomavirus, the cause of virtually all cervical cancers; and
WHEREAS, The United States Food and Drug Administration has
approved a vaccine for human papillomavirus, for both females
and males, with recommended inoculation beginning at 9 years of
age to 26 years of age, that prevents infection by four strains
of human papillomavirus to prevent most cases of cervical
cancer; and
WHEREAS, The National Immunization Program of the Centers for
Disease Control and Prevention and the Advisory Committee on
Immunization Practices have jointly recommended the use of the
human papillomavirus vaccine for adolescents and young adults,
both female and male, between 9 and 26 years of age; and
WHEREAS, Women are entitled to accurate information relating
20170HR0064PN0343 - 2 -
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30